Forward-looking
Statements
Certain statements in this presentation relating to Inuvo®, Inc. (“Inuvo”) or Vertro, Inc (“Vertro”) contain
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934. All forward-looking statements included in this presentation
are based on information available to Vertro and Inuvo as of the date hereof and Vertro and Inuvo
assume no obligation to update any forward-looking statements. These forward-looking statements are
not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of
which are beyond our control and difficult to predict and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements, including, without limitation, statements
made with respect to expectations with respect to the strategy, markets, synergies, costs, efficiencies, and
other anticipated financial impacts of the proposed transaction; the combined company’s plans,
objectives, expectations, and intentions with respect to future operations; approval of the proposed
transaction by stockholders of Inuvo and Vertro; the satisfaction of closing conditions to the proposed
transaction and the timing of the proposed transaction. All forward-looking statements involve significant
risks and uncertainties that could cause actual results to differ materially from those in the forward-looking
statements, many of which are generally outside the control of Inuvo and Vertro and are difficult to predict.
Examples of such risks and uncertainties include, but are not limited to, the possibility that the proposed
transaction is delayed or does not close, including due to the failure to receive required stockholder
approvals, the taking of governmental action (including the passage of legislation) to block the transaction,
or the failure to satisfy other closing conditions, and the possibility of adverse publicity or litigation,
including an adverse outcome thereof and the costs and expenses associated therewith. Additional key
risks are described in the filings made by each of Inuvo and Vertro filed with the U.S. Securities and
Exchange Commission, including their respective Form 10-Ks for the year ended December 31, 2010, and
Form 10-Qs for quarters ended March 31, 2011 and June 30, 2011.
2